Soleus Capital Management, L.P.
Position in TRVI — Trevi Therapeutics, Inc.
CIK 1802630
GREENWICH, CT
Position in TRVI
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$19,326,600
+$8,058,600 QoQ
Shares Held
1,620,000
+80.0% QoQ
Ownership
1.14%
of shares outstanding
% of Portfolio
0.78%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Soleus Capital Management, L.P. holds $1,377,926,099 across 59 Biotechnology names. TRVI ranks #14 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KRYS |
Krystal Biotech, Inc.
|
1,153,087 | $297,865,433 | |
| 2 | CELC |
Celcuity Inc.
|
1,284,378 | $146,598,904 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
4,029,319 | $133,853,977 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
330,517 | $106,489,272 | |
| 5 | VCEL |
Vericel Corp
|
2,549,079 | $82,003,871 | |
| 6 | GERN |
Geron Corp
|
41,508,659 | $61,847,901 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
1,449,915 | $45,672,322 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
131,650 | $43,559,035 |
All Filings in TRVI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19,326,600 | 1,620,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $11,268,000 | 900,000 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $228,750 | 25,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,829,000 | 700,000 | Shares | Sole | 2025-08-15 | |
| No filing history on record for this holder in this stock. | ||||||